Foghorn TherapeuticsFHTX
FHTX
About: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Employees: 116
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
318% more call options, than puts
Call options by funds: $92K | Put options by funds: $22K
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
64% more capital invested
Capital invested by funds: $227M [Q2] → $372M (+$145M) [Q3]
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
10% more funds holding
Funds holding: 72 [Q2] → 79 (+7) [Q3]
0.88% more ownership
Funds ownership: 71.41% [Q2] → 72.29% (+0.88%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
82%
upside
Avg. target
$12
142%
upside
High target
$14
183%
upside
3 analyst ratings
2 positive
67%
1 neutral
33%
0 negative
0%
HC Wainwright & Co. Andrew Fein 30% 1-year accuracy 99 / 328 met price target | 163%upside $13 | Buy Reiterated | 17 Dec 2024 |
Jefferies Kelly Shi 50% 1-year accuracy 6 / 12 met price target | 183%upside $14 | Buy Maintained | 16 Dec 2024 |
Morgan Stanley Vikram Purohit 43% 1-year accuracy 3 / 7 met price target | 82%upside $9 | Equal-Weight Maintained | 24 Sept 2024 |
Financial journalist opinion
Based on 4 articles about FHTX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone
Negative
Zacks Investment Research
1 week ago
After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX)
The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
3 weeks ago
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
4 weeks ago
Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High?
The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Negative
Zacks Investment Research
1 month ago
Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.34 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC
Neutral
GlobeNewsWire
2 months ago
Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors
Primary target patient population for the FHD-909 Phase 1 trial is non-small cell lung cancer (NSCLC) Lilly leads the clinical development of the Phase 1 trial Foghorn's selective SMARCA2 oncology program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Lilly CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- October 10, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that the first patient has been dosed with FHD-909 (LY4050784) in the Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target patient population.
Neutral
GlobeNewsWire
2 months ago
Foghorn Therapeutics to Participate in the BMO Oncology Summit
CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Positive
Zacks Investment Research
3 months ago
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength?
Foghorn Therapeutics (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Charts implemented using Lightweight Charts™